(VIANEWS) – Good morning! Another day of trading is almost starting and here’s today’s list of stocks that have had significant trading activity in the US premarket session.
The three biggest winners today are ImmunoGen, Bionano Genomics, and Groupon.
| Rank | Financial Asset | Price | Premarket Change |
Updated (EST) |
|---|---|---|---|---|
| 1 | ImmunoGen (IMGN) | 4.50 | 2.97% | 2023-03-06 07:26:48 |
| 2 | Bionano Genomics (BNGO) | 1.42 | 2.9% | 2023-03-06 07:31:27 |
| 3 | Groupon (GRPN) | 7.00 | 2.64% | 2023-03-06 04:11:20 |
| 4 | Matterport (MTTR) |
3.03 | 2.02% | 2023-03-06 07:28:17 |
| 5 | Matterport (MTTR) |
3.03 | 2.02% | 2023-03-06 07:28:17 |
| 6 | Globalstar (GSAT) | 1.27 | 1.6% | 2023-03-06 05:07:41 |
| 7 | FuboTV (FUBO) | 1.71 | 1.18% | 2023-03-06 05:07:24 |
| 8 | Aurora Cannabis (ACB) | 0.86 | 1.08% | 2023-03-06 05:07:44 |
| 9 | Manulife Financial (MFC) | 20.34 | 0.84% | 2023-03-06 04:45:32 |
| 10 | UBS Group (UBS) | 22.28 | 0.72% | 2023-03-06 05:05:43 |
The three biggest losers today are Xenetic Biosciences, Aspen Group, and Arcturus Therapeutics.
| Rank | Financial Asset | Price | Premarket Change |
Updated (EST) |
|---|---|---|---|---|
| 1 | Xenetic Biosciences (XBIO) | 0.41 | -15.21% | 2023-03-06 07:19:32 |
| 2 | Aspen Group (ASPU) | 0.22 | -2.27% | 2023-03-06 07:31:12 |
| 3 | Arcturus Therapeutics (ARCT) | 16.18 | -1.82% | 2023-03-06 04:16:11 |
| 4 | MicroVision (MVIS) | 2.47 | -1.2% | 2023-03-06 07:13:05 |
| 5 | Momo (MOMO) | 9.19 | -1.18% | 2023-03-06 04:57:45 |
| 6 | BlackBerry (BB) | 4.08 | -0.97% | 2023-03-06 05:07:31 |
| 7 | Ryanair Holdings (RYAAY) | 96.47 | -0.84% | 2023-03-06 04:36:31 |
| 8 | AbbVie (ABBV) | 154.78 | -0.82% | 2023-03-06 04:38:20 |
| 9 | BCE (BCE) | 44.26 | -0.58% | 2023-03-06 04:39:43 |
| 10 | Randgold (GOLD) | 16.43 | -0.54% | 2023-03-06 07:26:06 |
Premarket Winners today
1. ImmunoGen (IMGN) – Premarket: 2.97%
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
NASDAQ ended the session with ImmunoGen sliding 1.91% to $4.37 on Monday while NASDAQ jumped 1.97% to $11,689.01.
Earnings Per Share
As for profitability, ImmunoGen has a trailing twelve months EPS of $-0.252.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -157.66%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ImmunoGen’s stock is considered to be oversold (<=20).
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 76.5% and a negative 180%, respectively.
Volatility
ImmunoGen’s last week, last month’s, and last quarter’s current intraday variation average was a positive 3.25%, a negative 0.82%, and a positive 3.07%.
ImmunoGen’s highest amplitude of average volatility was 4.17% (last week), 3.57% (last month), and 3.07% (last quarter).
More news about ImmunoGen.
2. Bionano Genomics (BNGO) – Premarket: 2.9%
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
NASDAQ ended the session with Bionano Genomics jumping 1.47% to $1.38 on Monday, after two sequential sessions in a row of gains. NASDAQ jumped 1.97% to $11,689.01, after two sequential sessions in a row of gains, on what was an all-around up trend trading session today.
Earnings Per Share
As for profitability, Bionano Genomics has a trailing twelve months EPS of $-0.394.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -37.5%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 55.1%, now sitting on 25.89M for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Bionano Genomics’s stock is considered to be oversold (<=20).
Volatility
Bionano Genomics’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.52%, a negative 1.93%, and a positive 4.05%.
Bionano Genomics’s highest amplitude of average volatility was 3.06% (last week), 3.77% (last month), and 4.05% (last quarter).
More news about Bionano Genomics.
3. Groupon (GRPN) – Premarket: 2.64%
Groupon, Inc., together with its subsidiaries, operates a marketplace that connects consumers to merchants. It operates in two segments, North America and International. The company sells goods or services on behalf of third-party merchants; and first-party goods inventory. It serves customers through its mobile applications and websites. The company was formerly known as ThePoint.com, Inc. and changed its name to Groupon, Inc. in October 2008. Groupon, Inc. was incorporated in 2008 and is headquartered in Chicago, Illinois.
NASDAQ ended the session with Groupon jumping 1.04% to $6.82 on Monday while NASDAQ rose 1.97% to $11,689.01.
Earnings Per Share
As for profitability, Groupon has a trailing twelve months EPS of $-10.07.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -121.5%.
Volatility
Groupon’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.15%, a negative 1.01%, and a positive 3.90%.
Groupon’s highest amplitude of average volatility was 3.42% (last week), 2.86% (last month), and 3.90% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Groupon’s stock is considered to be overbought (>=80).
More news about Groupon.
4. Matterport
(MTTR) – Premarket: 2.02%
Matterport, Inc., a spatial data company, focuses on digitization and datafication of the built world. It offers Matterport digital twins, a 3D data platform to design, build, operate, promote, and understand spaces. The company offers Matterport Capture, an application that enables to capture depth, data, and imagery of a space using 3D cameras, 360 cameras, and iPhones; Matterport Workshop application to customize, add additional details, and share spaces; Matterport Showcase application for audience view and explore space in its final format; and Matterport VR to experience virtual reality. It offers solutions for real estate, photography, travel and hospitality, retail, insurance and restoration, industrial and facilities management, architecture, and engineering and construction industries. Matterport, Inc. was founded in 2011 and is headquartered in Sunnyvale, California.
NASDAQ ended the session with Matterport
rising 4.43% to $2.97 on Monday while NASDAQ rose 1.97% to $11,689.01.
Earnings Per Share
As for profitability, Matterport
has a trailing twelve months EPS of $-3.367.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -52.24%.
Volatility
Matterport
‘s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.69%, a negative 1.29%, and a positive 3.58%.
Matterport
‘s highest amplitude of average volatility was 3.02% (last week), 3.53% (last month), and 3.58% (last quarter).
Volume
Today’s last reported volume for Matterport
is 2899580 which is 8.76% below its average volume of 3178030.
Revenue Growth
Year-on-year quarterly revenue growth grew by 37.4%, now sitting on 122.07M for the twelve trailing months.
More news about Matterport
.
5. Matterport
(MTTR) – Premarket: 2.02%
Matterport, Inc., a spatial data company, focuses on digitization and datafication of the built world. It offers Matterport digital twins, a 3D data platform to design, build, operate, promote, and understand spaces. The company offers Matterport Capture, an application that enables to capture depth, data, and imagery of a space using 3D cameras, 360 cameras, and iPhones; Matterport Workshop application to customize, add additional details, and share spaces; Matterport Showcase application for audience view and explore space in its final format; and Matterport VR to experience virtual reality. It offers solutions for real estate, photography, travel and hospitality, retail, insurance and restoration, industrial and facilities management, architecture, and engineering and construction industries. Matterport, Inc. was founded in 2011 and is headquartered in Sunnyvale, California.
NASDAQ ended the session with Matterport
rising 4.43% to $2.97 on Monday, after two sequential sessions in a row of gains. NASDAQ rose 1.97% to $11,689.01, after two successive sessions in a row of gains, on what was an all-around positive trend trading session today.
Earnings Per Share
As for profitability, Matterport
has a trailing twelve months EPS of $-3.367.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -52.24%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 37.4%, now sitting on 122.07M for the twelve trailing months.
Yearly Top and Bottom Value
Matterport
‘s stock is valued at $2.97 at 07:34 EST, way below its 52-week high of $9.36 and way higher than its 52-week low of $2.37.
More news about Matterport
.
6. Globalstar (GSAT) – Premarket: 1.6%
Globalstar, Inc. provides mobile satellite services worldwide. The company offers duplex two-way voice and data products, including mobile voice and data satellite communications services and equipment for remote business continuity, recreational usage, safety, emergency preparedness and response, and other applications; fixed voice and data satellite communications services and equipment at industrial, commercial, and residential sites, as well as rural villages and ships; and data modem services and equipment. It also provides SPOT consumer retail products, such as SPOT satellite GPS messenger for personal tracking, emergency location, and messaging solutions; and SPOT Trace, an anti-theft and asset tracking device. In addition, the company offers commercial Internet of Things one-way transmission products to track cargo containers and rail cars, as well as to monitor utility meters, and oil and gas assets. Further, it sells wholesale minutes to independent gateway operators (IGOs); and provides engineering services, such as hardware and software designs to develop specific applications; and installation of gateways and antennas. The company distributes its products directly, as well as through independent agents, dealers and resellers, retailers, IGOs, and sales force and e-commerce Website. As of December 31, 2020, it had approximately 745,000 subscribers. The company primarily serves recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, construction, utilities, and transportation, as well as natural resources, mining, and forestry markets. Globalstar, Inc. has a strategic alliance with XCOM Labs to jointly commercialize XCOM's capacity-multiplying technology with Globalstar's Band n53 for 5G deployments in the United States and other countries where Globalstar has terrestrial rights. The company was founded in 1993 and is headquartered in Covington, Louisiana.
NYSE ended the session with Globalstar rising 4.62% to $1.25 on Monday while NYSE rose 1.27% to $15,721.06.
Earnings Per Share
As for profitability, Globalstar has a trailing twelve months EPS of $-0.07.
Sales Growth
Globalstar’s sales growth is negative 13.3% for the current quarter and negative 13.7% for the next.
Volatility
Globalstar’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.94%, a negative 0.55%, and a positive 3.76%.
Globalstar’s highest amplitude of average volatility was 6.18% (last week), 3.92% (last month), and 3.76% (last quarter).
Volume
Today’s last reported volume for Globalstar is 2794040 which is 28.9% below its average volume of 3929920.
More news about Globalstar.
7. FuboTV (FUBO) – Premarket: 1.18%
fuboTV Inc. operates a live TV streaming platform for live sports, news, and entertainment content in the United States and internationally. Its fuboTV platform allows customers to access content through streaming devices, as well as on SmartTVs, computers, mobile phones, and tablets. The company is headquartered in New York, New York.
NYSE ended the session with FuboTV sliding 0.59% to $1.69 on Monday, after five successive sessions in a row of losses. NYSE jumped 1.27% to $15,721.06, after three sequential sessions in a row of gains, on what was an all-around up trend trading session today.
Earnings Per Share
As for profitability, FuboTV has a trailing twelve months EPS of $-3.735.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -66.53%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 102.2%, now sitting on 760.65M for the twelve trailing months.
More news about FuboTV.
8. Aurora Cannabis (ACB) – Premarket: 1.08%
Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, Caribbeans, South America, and Israel; and distribution and sale of hemp-derived cannabidiol (CBD) products in the United States (U.S.) market. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, and cannabis extracts, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried milled strains and strain specific cannabis oils. Further, it offers patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
NYSE ended the session with Aurora Cannabis rising 3.34% to $0.85 on Monday while NYSE rose 1.27% to $15,721.06.
Earnings Per Share
As for profitability, Aurora Cannabis has a trailing twelve months EPS of $-15.749.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -134.22%.
Yearly Top and Bottom Value
Aurora Cannabis’s stock is valued at $0.85 at 07:34 EST, way below its 52-week high of $4.56 and higher than its 52-week low of $0.81.
Sales Growth
Aurora Cannabis’s sales growth is 25.2% for the current quarter and 29.7% for the next.
More news about Aurora Cannabis.
9. Manulife Financial (MFC) – Premarket: 0.84%
Manulife Financial Corporation, together with its subsidiaries, provides financial products and services in Asia, Canada, the United States, and internationally. The company operates through Wealth and Asset Management Businesses; Insurance and Annuity Products; And Corporate and Other segments. The Wealth and Asset Management Businesses segment provides mutual funds and exchange-traded funds, group retirement and savings products, and institutional asset management services through agents and brokers affiliated with the company, securities brokerage firms, and financial advisors pension plan consultants and banks. The Insurance and Annuity Products segment offers deposit and credit products; individual life, and individual and group long-term care insurance; and guaranteed and partially guaranteed annuity products through insurance agents, brokers, banks, financial planners, and direct marketing. The Corporate and Other segment is involved in property and casualty insurance and reinsurance businesses; and run-off reinsurance operations, including variable annuities, and accident and health. It also manages timberland and agricultural portfolios; and engages in insurance agency, portfolio and mutual fund management, mutual fund dealer, life, annuity, long-term care, and financial reinsurance; and fund management businesses. Additionally, the company holds and manages provides investment management, counseling, advisory, and dealer services. Manulife Financial Corporation was incorporated in 1887 and is headquartered in Toronto, Canada.
NYSE ended the session with Manulife Financial rising 0.98% to $20.17 on Monday while NYSE rose 1.27% to $15,721.06.
Earnings Per Share
As for profitability, Manulife Financial has a trailing twelve months EPS of $2.39.
PE Ratio
Manulife Financial has a trailing twelve months price to earnings ratio of 8.45. Meaning, the purchaser of the share is investing $8.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.93%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 52.7%, now sitting on 21.53B for the twelve trailing months.
More news about Manulife Financial.
10. UBS Group (UBS) – Premarket: 0.72%
UBS Group AG provides financial advice and solutions to private, institutional, and corporate clients worldwide. It operates through four divisions: Global Wealth Management, Personal & Corporate Banking, Asset Management, and Investment Bank. The Global Wealth Management division offers investment advice and solutions, and lending solutions to ultra high net worth and high net worth clients. This segment also provides estate and wealth planning, investing, philanthropy, corporate and banking, and family advisory services, as well as mortgage, securities-based, and structured lending solutions. The Personal & Corporate Banking division provides personal banking products and services, such as deposits, cards, and online and mobile banking, as well as lending, investments, and retirement services; and corporate and institutional solutions, including equity and debt capital markets, syndicated and structured credit, private placements, leasing, traditional financing, trade and export finance, and global custody solutions, as well as transaction banking solutions for payment and cash management. The Asset Management division offers equities, fixed income, hedge funds, real estate and private markets, indexed and alternative beta strategies, asset allocation and currency investment strategies, customized multi-asset solutions, advisory and fiduciary services, and multi-manager hedge fund solutions and advisory services. The Investment Bank division advises clients on strategic business opportunities and helps them raise capital to fund their activities; enables its clients to buy, sell, and finance securities on capital markets and to manage their risks and liquidity; and offers clients differentiated content on major financial markets and securities. The company was formerly known as UBS AG and changed its name to UBS Group AG in December 2014. UBS Group AG was founded in 1862 and is based in Zurich, Switzerland.
NYSE ended the session with UBS Group jumping 3.1% to $22.12 on Monday, after two consecutive sessions in a row of gains. NYSE jumped 1.27% to $15,721.06, after three sequential sessions in a row of gains, on what was an all-around positive trend trading session today.
Earnings Per Share
As for profitability, UBS Group has a trailing twelve months EPS of $1.83.
PE Ratio
UBS Group has a trailing twelve months price to earnings ratio of 12.08. Meaning, the purchaser of the share is investing $12.08 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.96%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Apr 11, 2023, the estimated forward annual dividend rate is 0.28 and the estimated forward annual dividend yield is 1.27%.
Moving Average
UBS Group’s worth is above its 50-day moving average of $20.19 and way higher than its 200-day moving average of $17.43.
More news about UBS Group.
Premarket Losers Today
1. Xenetic Biosciences (XBIO) – Premarket: -15.21%
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
NASDAQ ended the session with Xenetic Biosciences falling 3.18% to $0.48 on Monday, after five consecutive sessions in a row of losses. NASDAQ rose 1.97% to $11,689.01, after two consecutive sessions in a row of gains, on what was an all-around bullish trend trading session today.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-1.704.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.85%.
Yearly Top and Bottom Value
Xenetic Biosciences’s stock is valued at $0.48 at 07:34 EST, way under its 52-week high of $1.25 and way higher than its 52-week low of $0.24.
More news about Xenetic Biosciences.
2. Aspen Group (ASPU) – Premarket: -2.27%
Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.
NASDAQ ended the session with Aspen Group rising 7.65% to $0.22 on Monday, after four successive sessions in a row of gains. NASDAQ rose 1.97% to $11,689.01, after two consecutive sessions in a row of gains, on what was an all-around up trend trading session today.
Earnings Per Share
As for profitability, Aspen Group has a trailing twelve months EPS of $-0.383.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -28.28%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 9.9%, now sitting on 74.29M for the twelve trailing months.
Sales Growth
Aspen Group’s sales growth is negative 23.5% for the ongoing quarter and negative 25.9% for the next.
More news about Aspen Group.
3. Arcturus Therapeutics (ARCT) – Premarket: -1.82%
Arcturus Therapeutics Holdings Inc. operates as a late-stage clinical mRNA medicines and vaccines company. Its technologies include LUNAR lipid-mediated delivery; STARR mRNA Technology (samRNA); and mRNA drug substance. The company's pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis with partnered programs, including glycogen storage disease type III and hepatitis B virus. Its RNA therapeutics platforms can be applied in multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Its technologies are covered by its patent portfolio, including patents and patent applications issued in the U.S., Europe, Japan, China, and other countries. The company was founded in 2013 and is headquartered in San Diego, California.
NASDAQ ended the session with Arcturus Therapeutics rising 3.55% to $16.48 on Monday, following the last session’s upward trend. NASDAQ jumped 1.97% to $11,689.01, after two sequential sessions in a row of gains, on what was an all-around bullish trend exchanging session today.
Earnings Per Share
As for profitability, Arcturus Therapeutics has a trailing twelve months EPS of $-3.55.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -72.46%.
Volume
Today’s last reported volume for Arcturus Therapeutics is 112963 which is 72.62% below its average volume of 412650.
Sales Growth
Arcturus Therapeutics’s sales growth is 1154.4% for the ongoing quarter and 1235.8% for the next.
More news about Arcturus Therapeutics.
4. MicroVision (MVIS) – Premarket: -1.2%
MicroVision, Inc. develops lidar sensors used in automotive safety and autonomous driving applications. Its laser beam scanning technology is based on micro-electrical mechanical systems, laser diodes, opto-mechanics, electronics, algorithms, and software. The company also develops micro-display concepts and designs for head-mounted augmented reality (AR) headsets, as well as 1440i MEMS module that can support AR headsets; Interactive Display modules used in smart speakers and other devices; and Consumer Lidar used in smart home systems. In addition, it provides PicoP, a scanning technology that creates full color, high-contrast, and uniform image over the entire field-of-view from a small and thin module. Further, the company develops 1st generation long range lidar. The company sells its products primarily to original equipment manufacturers and original design manufacturers. MicroVision, Inc. was founded in 1993 and is headquartered in Redmond, Washington.
NASDAQ ended the session with MicroVision rising 1.94% to $2.50 on Monday, after two consecutive sessions in a row of gains. NASDAQ rose 1.97% to $11,689.01, after two sequential sessions in a row of gains, on what was an all-around up trend exchanging session today.
Earnings Per Share
As for profitability, MicroVision has a trailing twelve months EPS of $-0.102.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -50.24%.
More news about MicroVision.
5. Momo (MOMO) – Premarket: -1.18%
Hello Group Inc. provides mobile-based social and entertainment services in the People's Republic of China. It operates Momo platform that includes its Momo mobile application, as well as various related properties, features, functionalities, tools, and services. The company's Momo mobile application connects people and facilitates interactions based on location and interests; and various recreational activities, including live talent shows, short videos, and social games, as well as other video- and audio-based interactive experiences, such as online parties, mobile karaoke, and user participated reality shows. It also operates Tantan, a social and dating application, which enables users to find and establish romantic connections, and meet interesting people; and provides live video, quick chat, value-added, mobile marketing, and other services, as well as mobile games and audio chatrooms. In addition, it allows its platform's users to livestream a variety of content and activities that comprise talent shows, such as singing, dancing, and talk shows, as well as casual chatting, and other forms of interactions between broadcasters and viewers. The company was formerly known as Momo Inc. and changed its name to Hello Group Inc. in August 2021. Hello Group Inc. was incorporated in 2011 and is headquartered in Beijing, the People's Republic of China.
NASDAQ ended the session with Momo rising 1.53% to $9.30 on Monday, after three consecutive sessions in a row of gains. NASDAQ jumped 1.97% to $11,689.01, after two consecutive sessions in a row of gains, on what was an all-around bullish trend exchanging session today.
Earnings Per Share
As for profitability, Momo has a trailing twelve months EPS of $1.49.
PE Ratio
Momo has a trailing twelve months price to earnings ratio of 6.23. Meaning, the purchaser of the share is investing $6.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.97%.
More news about Momo.
6. BlackBerry (BB) – Premarket: -0.97%
BlackBerry Limited provides intelligent security software and services to enterprises and governments worldwide. The company operates through three segments: Cybersecurity, IoT, and Licensing and Other. The company offers BlackBerry Cyber Suite, which provides Cylance AI and machine learning-based cybersecurity solutions, including BlackBerry Protect, an EPP and available MTD solution; BlackBerry Optics, an EDR solution that provides visibility into and prevention of malicious activity; BlackBerry Guard, a managed detection and response solution; BlackBerry Gateway, an AI-empowered ZTNA solution; and BlackBerry Persona, a UEBA solution that provides authentication by validating user identity in real time. It also provides BlackBerry Spark Unified Endpoint Management Suite, such as BlackBerry UEM, a central software component of its secure communications platform; BlackBerry Dynamics that provides a development platform and secure container for mobile applications; BlackBerry AtHoc and BlackBerry Alert secure and networked critical event management solutions; and SecuSUITE for Government, a multi-OS voice and text messaging solution, as well as BBM Enterprise, an enterprise-grade secure instant messaging solution. In addition, the company offers BlackBerry QNX, which provides Neutrino operating system and BlackBerry QNX CAR platform, and other products; BlackBerry QNX, an embedded system solution; BlackBerry Jarvis, a cloud-based binary static application security testing platform; BlackBerry Certicom cryptography and management products, and BlackBerry Radar asset monitoring solution; and BlackBerry IVY, an intelligent vehicle data platform, as well as enterprise and cybersecurity consulting services. Further, it is involved in the patent licensing and legacy service access fees business. As of February 28, 2022, it owned approximately 38,000 worldwide patents and applications. BlackBerry Limited was incorporated in 1984 and is headquartered in Waterloo, Canada.
NYSE ended the session with BlackBerry jumping 4.3% to $4.12 on Monday, after four consecutive sessions in a row of gains. NYSE rose 1.27% to $15,721.06, after three successive sessions in a row of gains, on what was an all-around positive trend exchanging session today.
Earnings Per Share
As for profitability, BlackBerry has a trailing twelve months EPS of $-1.97.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.78%.
Moving Average
BlackBerry’s worth is way under its 50-day moving average of $6.10 and way under its 200-day moving average of $8.33.
Volatility
BlackBerry’s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.04%, a negative 0.50%, and a positive 2.62%.
BlackBerry’s highest amplitude of average volatility was 2.91% (last week), 2.25% (last month), and 2.62% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth declined by 11.9%, now sitting on 718M for the twelve trailing months.
More news about BlackBerry.
7. Ryanair Holdings (RYAAY) – Premarket: -0.84%
Ryanair Holdings plc, together with its subsidiaries, provides scheduled-passenger airline services in Ireland, the United Kingdom, Italy, Spain, Germany, and other European countries. It is also involved in the provision of various ancillary services, such as non-flight scheduled and Internet-related services; in-flight sale of beverages, food, duty-free, and merchandise; and marketing of car hire and accommodation services, and travel insurance through its website and mobile app. In addition, the company offers aircraft and passenger handling, ticketing, and maintenance and repair services; and markets car parking, fast-track, airport transfers, attractions, and activities on its website and mobile app, as well as sells gift vouchers. As of June 30, 2022, it had a principal fleet of approximately 483 Boeing 737 aircrafts and 29 Airbus A320 aircrafts; and offered approximately 3,000 short-haul flights per day serving approximately 225 airports. Ryanair Holdings plc was founded in 1985 and is headquartered in Swords, Ireland.
NASDAQ ended the session with Ryanair Holdings jumping 2.28% to $97.29 on Monday, after four successive sessions in a row of gains. NASDAQ rose 1.97% to $11,689.01, after two consecutive sessions in a row of gains, on what was an all-around positive trend exchanging session today.
Earnings Per Share
As for profitability, Ryanair Holdings has a trailing twelve months EPS of $-7.24.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.39%.
More news about Ryanair Holdings.
8. AbbVie (ABBV) – Premarket: -0.82%
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
NYSE ended the session with AbbVie jumping 1.09% to $156.06 on Monday, following the last session’s upward trend. NYSE rose 1.27% to $15,721.06, after three successive sessions in a row of gains, on what was an all-around bullish trend exchanging session today.
Earnings Per Share
As for profitability, AbbVie has a trailing twelve months EPS of $2.91.
PE Ratio
AbbVie has a trailing twelve months price to earnings ratio of 53.57. Meaning, the purchaser of the share is investing $53.57 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 90.65%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 3.3%, now sitting on 57.82B for the twelve trailing months.
Moving Average
AbbVie’s value is above its 50-day moving average of $154.46 and higher than its 200-day moving average of $149.00.
Sales Growth
AbbVie’s sales growth is negative 3% for the ongoing quarter and negative 5.6% for the next.
Yearly Top and Bottom Value
AbbVie’s stock is valued at $156.06 at 07:34 EST, way under its 52-week high of $175.91 and way higher than its 52-week low of $134.09.
More news about AbbVie.
9. BCE (BCE) – Premarket: -0.58%
BCE Inc., a telecommunications and media company, provides wireless, wireline, Internet, and television (TV) services to residential, business, and wholesale customers in Canada. The company operates through three segments: Bell Wireless, Bell Wireline, and Bell Media. The Bell Wireless segment offers wireless voice and data communication products and services, as well as consumer electronics products. The Bell Wireline segment offers data, including internet access and Internet protocol television (IPTV), local telephone, and long distance services, as well as other communication services and products; and satellite TV service and connectivity servuces. This segment also buys and sells local telephone, long distance, data, and other services from or to resellers and other carriers. The Bell Media segment provides conventional TV, specialty TV, pay TV, streaming services, digital media services, radio broadcasting services, and out-of-home advertising services. BCE Inc. was founded in 1880 and is headquartered in Verdun, Canada.
NYSE ended the session with BCE jumping 1.14% to $44.52 on Monday, following the last session’s upward trend. NYSE rose 1.27% to $15,721.06, after three consecutive sessions in a row of gains, on what was an all-around positive trend trading session today.
Earnings Per Share
As for profitability, BCE has a trailing twelve months EPS of $2.21.
PE Ratio
BCE has a trailing twelve months price to earnings ratio of 20.1. Meaning, the purchaser of the share is investing $20.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.87%.
Sales Growth
BCE’s sales growth is 2% for the current quarter and 2.2% for the next.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BCE’s stock is considered to be oversold (<=20).
More news about BCE.
10. Randgold (GOLD) – Premarket: -0.54%
Barrick Gold Corporation engages in the exploration, mine development, production, and sale of gold and copper properties. It has ownership interests in producing gold mines that are located in Argentina, Canada, Côte d'Ivoire, the Democratic Republic of Congo, Dominican Republic, Mali, Tanzania, and the United States. The company also has ownership interests in producing copper mines located in Chile, Saudi Arabia, and Zambia; and various other projects located throughout the Americas and Africa. Barrick Gold Corporation was founded in 1983 and is headquartered in Toronto, Canada.
NASDAQ ended the session with Randgold jumping 0.89% to $16.52 on Monday while NASDAQ jumped 1.97% to $11,689.01.
Earnings Per Share
As for profitability, Randgold has a trailing twelve months EPS of $1.31.
PE Ratio
Randgold has a trailing twelve months price to earnings ratio of 12.64. Meaning, the purchaser of the share is investing $12.64 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.27%.
Moving Average
Randgold’s worth is under its 50-day moving average of $18.13 and below its 200-day moving average of $17.10.
Revenue Growth
Year-on-year quarterly revenue growth declined by 10.6%, now sitting on 11.55B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 65.7% and a negative 19.2%, respectively.
More news about Randgold.
Stay up to date with our premarket winners and losers daily report
